Evidence map›Paper›PMID 36312666›Full record

ArticleCureus2022

Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma.

Zachary Wolfe, Aaron Blackham, Alyson McIntosh, Angela Miller, Hina Sheikh, Suresh Nair

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zachary WolfeHematology and Medical Oncology, Lehigh Valley Topper Cancer Institute, Allentown, USA.
Aaron BlackhamSurgical Oncology, Lehigh Valley Topper Cancer Institute, Allentown, USA.
Alyson McIntoshRadiation Oncology, Lehigh Valley Cancer Institute, Allentown, USA.
Angela MillerHematology and Medical Oncology, Lehigh Valley Topper Cancer Institute, Allentown, USA.
Hina SheikhPathology, Health Network Laboratories, Allentown, USA.
Suresh NairHematology and Oncology, Lehigh Valley Cancer Institute, Allentown, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic melanoma refractory to checkpoint inhibitors is a challenging clinical scenario. We present the case of a patient who was refractory to standard of care but was able to achieve a durable complete remission with the combination of stereotactic body radiation therapy (SBRT), talimogene laherparepvec (TVEC), and ipilimumab.

Indexed as

immunotherapymelanomaoncolytic virusesradiation therapytargeted therapeutics

Identifiers

PMID36312666
PMCPMC9596194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.